Sana Biotechnology (SANA) Cash from Financing Activities (2020 - 2026)

Sana Biotechnology's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$128000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 113.03% year-over-year to -$128000.0; the TTM figure through Mar 2026 stood at $127.6 million (up 790.35% YoY), while the FY2025 annual figure was $128.7 million, down 35.55% from the prior year.
• Cash from Financing Activities came in at -$128000.0 for Q1 2026 at Sana Biotechnology, down from $17.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $186.4 million in Q1 2024 to a low of -$128000.0 in Q1 2026.
• A 5-year average of $21.5 million and a median of $1.6 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 78881.78% in 2024 and tumbled 113.03% in 2026, its largest moves.
• Sana Biotechnology's Cash from Financing Activities stood at $1.1 million in 2022, then surged by 61.92% to $1.7 million in 2023, then slumped by 62.57% to $643000.0 in 2024, then soared by 2644.95% to $17.6 million in 2025, then plunged by 100.73% to -$128000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$128000.0, $17.6 million, and $109.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison